Sommeil
In Frankreich gemeldetes Nahrungsergänzungsmittel, Meldung Nr. 2023-10-280, Entscheidung vom 6. Oktober 2023
Sommeil (Biophénix) ist ein in Frankreich gemeldetes Nahrungsergänzungsmittel. Status: in Frankreich gemeldet, Inverkehrbringen möglich. Hauptbestandteile: Griffonia simplicifolia 300 mg pro Tag, Melissa officinalis 300 mg pro Tag, Ocimum tenuiflorum 250 mg pro Tag, Mélatonine. 1 Punkt in seiner Zusammensetzung erfordert eine Prüfung (verbotener Stoff, Dosis oder neuartiges Lebensmittel).
- Marke
- Biophénix
- Für das Inverkehrbringen verantwortlich
- GREEN TIME SA
- Status
- In Frankreich gemeldet, Inverkehrbringen möglich: Die Verwaltung hat der Meldung nicht widersprochen (weder Zulassung noch Sicherheitsbewertung)
- Form
- Kapsel
- Tagesdosis
Originaltext auf Französisch.
2 gélules par jour
- Gebrauchsanweisung
Originaltext auf Französisch.
2 gélules par jour avec un peu d'eau
- Nicht empfohlen (laut Hersteller)
- Jugendliche (unter 18 Jahren), Stillende, Schwangere, Einnahme von Blutdrucksenkern, Längere Anwendung
- Vom Hersteller angegebene Ziele (keine zugelassenen gesundheitsbezogenen Angaben)
- Schlaf
Meldung 135474, Verfahren Article 15. Compl’Alim, Meldungen von Nahrungsergänzungsmitteln, abgerufen am 15. November 2026.
Deklarierte Zusammensetzung
Pflanzen
| Pflanze | Teil | Zubereitung | Täglich |
|---|---|---|---|
| Griffonia simplicifolia (DC.) Baill. | Graine | Extrait sec aqueux | 300 mg |
| Melissa officinalis L. | Feuille | Extrait sec aqueux | 300 mg |
| Ocimum tenuiflorum L. | Feuille | Extrait fluide hydroalcoolique | 250 mg |
Weitere aktive Inhaltsstoffe
| Name | Täglich |
|---|---|
| Mélatonine | nicht gemeldet |
Zusatzstoffe
Hydroxypropyl Méthyl Cellulose
Liste aus der Meldung, behördliche Entscheidung vom (Compl’Alim, Meldungen von Nahrungsergänzungsmitteln).
Warnhinweise auf dem Etikett
Originaltext auf Französisch.
Réservé à l'adulteRechtliche Prüfpunkte
- Substance interdite
Griffonia simplicifolia (DC.) Baill.: gefährliche Pflanze, in Lebensmitteln in Belgien verboten (Liste 1).
Quelle: Belgien, Königlicher Erlass vom 31. August 2021, Pflanzenlisten (Anhang am 30. Januar 2024 ersetzt), arrêté royal du 31 août 2021, annexe remplacée le 30 janvier 2024, liste 1, page PDF 73.
Diese Angaben geben die Meldung des Herstellers bei der Verwaltung (DGAL) wieder. Sie besagen nicht, ob das Produkt wirksam ist, und ersetzen keinen ärztlichen oder pharmazeutischen Rat, insbesondere während Schwangerschaft oder medikamentöser Behandlung.
Offizielle Warnhinweise (Health Canada)
Health Canada veröffentlicht Warnhinweise zu diesen Zutaten:
- Melissa officinalis L.
Warnhinweis, Geltungsbedingung und zitierte Studien lesen
Offizieller Originaltext auf Englisch.
LEMON BALM -MELISSA OFFICINALIS
Art der Anwendung: Oral
Vorsichtsmaßnahmen und Warnhinweise
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2014).
Von Health Canada zitierte Quellen (1)
- EMA 2014. European Medicines Agency. Melissae folium.. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 16 June2014. [Accessed 2023 October 27]. Available at: https://www.ema.europa.eu/en/medicines/herbal/melissae-folium
When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2014).
Von Health Canada zitierte Quellen (1)
- EMA 2014. European Medicines Agency. Melissae folium.. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 16 June2014. [Accessed 2023 October 27]. Available at: https://www.ema.europa.eu/en/medicines/herbal/melissae-folium
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
- Ocimum tenuiflorum L.
Warnhinweis, Geltungsbedingung und zitierte Studien lesen
Offizieller Originaltext auf Englisch.
HOLY BASIL - OCIMUM TENUIFLORUM - SEED
Art der Anwendung: Oral
Vorsichtsmaßnahmen und Warnhinweise
Anwendungsbedingung: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a cardiovascular condition (Rai et al. 1997; Agrawal et al. 1996).
Von Health Canada zitierte Quellen (2)
- Agrawal P, Rai V, Singh RB. Randomized placebo-controlled, single blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus. International Journal of Clinical Pharmacology and Therapeutics 1996;34(9):406-409. PubMed Randomisierte Studie
- Rai V, Iyer U, Mani UV. Effect of Ocimum sanctum leaf powder on blood lipoproteins, glycated proteins and total amino acids in patients with non-insulin-dependent diabetes mellitus. Journal of Nutritional and Environmental Medicine. 1997;7(2):133-118. PubMed
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking any heart or blood pressure medication (Rai et al. 1997; Agrawal et al. 1996).
Von Health Canada zitierte Quellen (2)
- Agrawal P, Rai V, Singh RB. Randomized placebo-controlled, single blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus. International Journal of Clinical Pharmacology and Therapeutics 1996;34(9):406-409. PubMed Randomisierte Studie
- Rai V, Iyer U, Mani UV. Effect of Ocimum sanctum leaf powder on blood lipoproteins, glycated proteins and total amino acids in patients with non-insulin-dependent diabetes mellitus. Journal of Nutritional and Environmental Medicine. 1997;7(2):133-118. PubMed
Anwendungsbedingung: Relief of cough; Digestive aid.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Monografie von Health Canada vom 27. Februar 2026
HOLY BASIL - OCIMUM TENUIFLORUM - LEAF
Art der Anwendung: Oral
Vorsichtsmaßnahmen und Warnhinweise
Anwendungsbedingung: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (WHO 2002).
Von Health Canada zitierte Quellen (2)
- WHO 2002: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 2. Geneva (CH): World Health Organization; 2002.
- OMS 2002: Organisation mondiale de la santé (OMS). Monographs on Selected Medicinal Plants : Volume 1. Genève (CH) : Organisation mondiale de la santé; 2002.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a heart condition or diabetes (Rai et al. 1997; Agrawal et al. 1996).
Von Health Canada zitierte Quellen (2)
- Agrawal P, Rai V, Singh RB. Randomized placebo-controlled, single blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus. International Journal of Clinical Pharmacology and Therapeutics 1996;34(9):406-409. PubMed Randomisierte Studie
- Rai V, Iyer U, Mani UV. Effect of Ocimum sanctum leaf powder on blood lipoproteins, glycated proteins and total amino acids in patients with non-insulin-dependent diabetes mellitus. Journal of Nutritional and Environmental Medicine 1997;7(2):133-118. PubMed
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking any heart or blood pressure medication (Rai et al. 1997; Agrawal et al. 1996).
Von Health Canada zitierte Quellen (2)
- Agrawal P, Rai V, Singh RB. Randomized placebo-controlled, single blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus. International Journal of Clinical Pharmacology and Therapeutics 1996;34(9):406-409. PubMed Randomisierte Studie
- Rai V, Iyer U, Mani UV. Effect of Ocimum sanctum leaf powder on blood lipoproteins, glycated proteins and total amino acids in patients with non-insulin-dependent diabetes mellitus. Journal of Nutritional and Environmental Medicine 1997;7(2):133-118. PubMed
Anwendungsbedingung: Relief of cough/cold/respiratory mucus buildup; Digestive aid; Adaptogen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Gegenanzeigen
Do not use if you are pregnant (Prakash et al. 2005; Ahmed et al. 2002; WHO 2002; Wohlmuth 2002; Kapoor 2001).
Von Health Canada zitierte Quellen (6)
- Ahmed A, Ahamed RN, Aladakatti RH, Ghoseawar MG. Reversible antifertility effect of benzene extract of Ocimum sanctum on sperm parameters and fructose content in rats. Journal of basic and clinical physiology and pharmacology 2002;13:51-59. PubMed
- Kapoor LD. Handbook of Ayurvedic Medicinal Plants. Baton Roca (FL): CRC Press LLC; 2001.
- Prakash P, Gupta N. Therapeutic uses of Ocimum sanctum Linn (Tulsi) with a note on eugenol and its pharmacological actions: A short review. Indian Journal of Physiology and Pharmacology 2005;49(2):125-131. PubMed Übersichtsartikel
- WHO 2002: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 2. Geneva (CH): World Health Organization; 2002.
- Wohlmuth H. Sacred basil - an Ayurvedic adaptogen. Botanical Pathways, 2002; Issue 11.
- OMS 2002: Organisation mondiale de la santé (OMS). Monographs on Selected Medicinal Plants : Volume 1. Genève (CH) : Organisation mondiale de la santé; 2002.
- Mélatonine
Warnhinweis, Geltungsbedingung und zitierte Studien lesen
Offizieller Originaltext auf Englisch.
MELATONIN - Oral
Vorsichtsmaßnahmen und Warnhinweise
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications for seizure, blood pressure, to suppress the immune system, to affect mental state or increase sedation, steroids or blood thinners (Wirtz et al. 2008; IOM 2004; Herxheimer and Petrie 2002; Lusardi et al. 2000; Maestroni 1993).
Von Health Canada zitierte Quellen (5)
- Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database of Systematic Reviews 2002 Issue 2. Art. No.: CD001520. DOI: 10.1002/14651858.CD001520. [Accessed 2023 August 22]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958662/pdf/CD001520.pdf DOI
- IOM 2004: Institute of Medicine Committee on the Framework for Evaluating the Safety of Dietary Supplements. Prototype monograph on melatonin. Dietary Supplement Ingredient Prototype Monographs, Developed as Examples for the Report Dietary Supplements: A Framework for Evaluating Safety. Institute of Medicine and the National Research Council of the National Academies, Washington (DC): National Academies Press 2004: D1-D71.
- Lusardi P, Piazza E, Fogari R. Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study. British Journal of Clinical Pharmacology 2000;49:423-427. PubMed Randomisierte Studie
- Maestroni GJM. The immunoneuroendocrine role of melatonin. Journal of Pineal Research 1993;14(1):1-10. PubMed Übersichtsartikel
- Wirtz PH, Spillmann M, Bärtschi C, Ehlert U, von Känel R. Oral melatonin reduces blood coagulation activity: a placebo-controlled study in healthy young men. Journal of Pineal Research 2008;44:127-133. PubMed Randomisierte Studie
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have cardiovascular, immune, liver or kidney disease, seizure disorder, asthma or diabetes (Peschke and Mühlbauer 2010; Carrillo-Vico et al. 2005; IOM 2004; der Marderosian and Beuttlers 2003; Sutherland et al. 2003; Calvo et al. 2002; Herxheimer and Petrie 2002; Sutherland et al. 2002; Cagnacci et al. 2001a; Arangino et al. 1999; Sheldon 1998; Maestroni 1993).
Von Health Canada zitierte Quellen (12)
- Arangino S, Cagnacci A, Angiolucci M, Vacca AMB, Longu G, Volpe A, Melis GB. Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men. American Journal of Cardiology 1999; 83(9):1417-1419. PubMed Randomisierte Studie
- Cagnacci A, Arangino S, Renzi A, Paoletti AM, Melis GB, Cagnacci P, Volpe A. Influence of melatonin administration on glucose tolerance and insulin sensitivity of postmenopausal women. Clinical Endocrinology (Oxford) 2001a;54(3):339-346. PubMed Randomisierte Studie
- Calvo JR, Guerrero JM, Osuna C, Molinero P, Carrillo-Vico A. Melatonin triggers Crohn's disease symptoms. Journal of Pineal Research 2002;32(4):277-278. PubMed Fallbericht
- Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. Endocrine 2005;27:189-200. PubMed Übersichtsartikel
- der Marderosian A, Beutler JA, editors. 2003. The Review of Natural Health Products, 3rd edition. St. Louis (MO): Facts and Comparisons®, a Wolters Kluwer Company.
- Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database of Systematic Reviews 2002 Issue 2. Art. No.: CD001520. DOI: 10.1002/14651858.CD001520. [Accessed 2023 August 22]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958662/pdf/CD001520.pdf DOI
- IOM 2004: Institute of Medicine Committee on the Framework for Evaluating the Safety of Dietary Supplements. Prototype monograph on melatonin. Dietary Supplement Ingredient Prototype Monographs, Developed as Examples for the Report Dietary Supplements: A Framework for Evaluating Safety. Institute of Medicine and the National Research Council of the National Academies, Washington (DC): National Academies Press 2004: D1-D71.
- Maestroni GJM. The immunoneuroendocrine role of melatonin. Journal of Pineal Research 1993;14(1):1-10. PubMed Übersichtsartikel
- Peschke E, Mühlbauer E. New evidence for a role of melatonin in glucose regulation. Best practice & research. Clinical endocrinology & metabolism 2010;24(5):829-841. PubMed Übersichtsartikel
- Sheldon SH. Pro-convulsant effects of oral melatonin in neurologically disabled children. Lancet 1998;351:1254. PubMed
- Sutherland ER, Martin RJ, Ellison MC, Kraft M. Immunomodulatory effects of melatonin in asthma. American Journal of respiratory and critical care medicine 2002;166:1055-1061. PubMed
- Sutherland ER, Ellison MC, Kraft M, Martin RJ. Elevated serum melatonin is associated with the nocturnal worsening of asthma. Journal of Allergy and Clinical Immunology 2003;112(3):513-517. PubMed
1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).
When using this product avoid taking with alcohol or products that cause drowsiness (Herxheimer and Petrie 2002; Holliman and Chyka 1997).
Von Health Canada zitierte Quellen (1)
- Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database of Systematic Reviews 2002 Issue 2. Art. No.: CD001520. DOI: 10.1002/14651858.CD001520. [Accessed 2023 August 22]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958662/pdf/CD001520.pdf DOI
1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).
When using this product avoid driving or using machinery for 5 hours (Avery et al. 1998; Suhner et al. 1998b).
Von Health Canada zitierte Quellen (2)
- Avery D, Lenz M, Landis C. Guidelines for prescribing melatonin. Annals of Medicine 1998;30(1):122-130. PubMed Übersichtsartikel
- Suhner A, Schlagenhauf P, Tschopp A, Hauri-Bionda R, Friedrich-Koch A, Steffen R. Impact of melatonin on driving performance. Journal of Travel Medicine 1998b;5(1):7-13. PubMed Randomisierte Studie
Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists for more than 4 weeks (chronic insomnia) (Buscemi et al. 2004; IOM 2004; Dipiro et al. 2002).
Von Health Canada zitierte Quellen (3)
- Buscemi N, Vandermeer B, Pandya R, Hooton N, Tjosvold L, Hartling L, Baker G, Vohra S, Klassen T 2004. Melatonin for treatment of sleep disorders. Evidence Report/Technology Assessment No. 108. AHRQ Publication No. 05-E002-2. Rockville (MD): U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality. November, 2004.
- DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiological Approach. 5th edition. New York (NY): McGraw-Hill Co. Inc.; 2002.
- IOM 2004: Institute of Medicine Committee on the Framework for Evaluating the Safety of Dietary Supplements. Prototype monograph on melatonin. Dietary Supplement Ingredient Prototype Monographs, Developed as Examples for the Report Dietary Supplements: A Framework for Evaluating Safety. Institute of Medicine and the National Research Council of the National Academies, Washington (DC): National Academies Press 2004: D1-D71.
Gegenanzeigen
Do not use if you are pregnant or breastfeeding (IOM 2004).
Von Health Canada zitierte Quellen (1)
- IOM 2004: Institute of Medicine Committee on the Framework for Evaluating the Safety of Dietary Supplements. Prototype monograph on melatonin. Dietary Supplement Ingredient Prototype Monographs, Developed as Examples for the Report Dietary Supplements: A Framework for Evaluating Safety. Institute of Medicine and the National Research Council of the National Academies, Washington (DC): National Academies Press 2004: D1-D71.
Bekannte Nebenwirkungen
Stop use if allergy occurs or if you experience headache, confusion, or nausea (Herxheimer and Petrie 2002).
Von Health Canada zitierte Quellen (1)
- Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database of Systematic Reviews 2002 Issue 2. Art. No.: CD001520. DOI: 10.1002/14651858.CD001520. [Accessed 2023 August 22]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958662/pdf/CD001520.pdf DOI
Monografie von Health Canada vom 19. Dezember 2025
MELATONIN - Sublingual
Vorsichtsmaßnahmen und Warnhinweise
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications for seizure, blood pressure, to suppress the immune system, to affect mental state or increase sedation, steroids or blood thinners (Wirtz et al. 2008; IOM 2004; Herxheimer and Petrie 2002; Lusardi et al. 2000; Maestroni 1993).
Von Health Canada zitierte Quellen (5)
- Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database of Systematic Reviews Issue 2 2002. Art. No.: CD001520. DOI: 10.1002/14651858.CD001520. [Accessed 2023 August 22]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958662/pdf/CD001520.pdf DOI
- IOM 2004: Institute of Medicine Committee on the Framework for Evaluating the Safety of Dietary Supplements. Prototype monograph on melatonin. Dietary Supplement Ingredient Prototype Monographs, Developed as Examples for the Report Dietary Supplements: A Framework for Evaluating Safety. Institute of Medicine and the National Research Council of the National Academies, Washington (DC): National Academies Press 2004: D1-D71.
- Lusardi P, Piazza E, Fogari R. Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study. British Journal of Clinical Pharmacology 2000;49:423427. PubMed Randomisierte Studie
- Maestroni GJM. The immunoneuroendocrine role of melatonin. Journal of Pineal Research 1993;14(1):1-10. PubMed Übersichtsartikel
- Wirtz PH, Spillmann M, Bärtschi C, Ehlert U, von Känel R. Oral melatonin reduces blood coagulation activity: a placebo-controlled study in healthy young men. Journal of Pineal Research 2008;44:127-133. PubMed Randomisierte Studie
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a cardiovascular, immune, liver or kidney disease, seizure disorder, asthma or diabetes (Peschke and Mühlbauer 2010; Carrillo-Vico et al. 2005; IOM 2004; der Marderosian and Beuttlers 2003; Sutherland et al. 2003; Calvo et al. 2002; Herxheimer and Petrie 2002; Sutherland et al. 2002; Cagnacci et al. 2001a; Arangino et al. 1999; Sheldon 1998; Maestroni 1993).
Von Health Canada zitierte Quellen (12)
- Cagnacci A, Arangino S, Renzi A, Paoletti AM, Melis GB, Cagnacci P, Volpe A. Influence of melatonin administration on glucose tolerance and insulin sensitivity of postmenopausal women. Clinical Endocrinology (Oxford) 2001a;54(3):339-346. PubMed Randomisierte Studie
- Calvo JR, Guerrero JM, Osuna C, Molinero P, Carrillo-Vico A. Melatonin triggers Crohn's disease symptoms. Journal of Pineal Research 2002;32(4):277-278. PubMed Fallbericht
- Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. Endocrine 2005;27:189-200. PubMed Übersichtsartikel
- der Marderosian A, Beutters JA, editors. 2003. The Review of Natural Health Products, 3rd edition. St. Louis (MO): Facts and Comparisons®, a Wolters Kluwer Company.
- Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database of Systematic Reviews Issue 2 2002. Art. No.: CD001520. DOI: 10.1002/14651858.CD001520. [Accessed 2023 August 22]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958662/pdf/CD001520.pdf DOI
- IOM 2004: Institute of Medicine Committee on the Framework for Evaluating the Safety of Dietary Supplements. Prototype monograph on melatonin. Dietary Supplement Ingredient Prototype Monographs, Developed as Examples for the Report Dietary Supplements: A Framework for Evaluating Safety. Institute of Medicine and the National Research Council of the National Academies, Washington (DC): National Academies Press 2004: D1-D71.
- Maestroni GJM. The immunoneuroendocrine role of melatonin. Journal of Pineal Research 1993;14(1):1-10. PubMed Übersichtsartikel
- Peschke E, Mühlbauer E. New evidence for a role of melatonin in glucose regulation. Best practice & research. Clinical endocrinology & metabolism 2010;24(5):829-841. PubMed Übersichtsartikel
- Sheldon SH. Pro-convulsant effects of oral melatonin in neurologically disabled children. Lancet 1998;351:1254. PubMed
- Sutherland ER, Martin RJ, Ellison MC, Kraft M. Immunomodulatory effects of melatonin in asthma. American Journal of respiratory and critical care medicine 2002;166:1055-1061. PubMed
- Sutherland ER, Ellison MC, Kraft M, Martin RJ. Elevated serum melatonin is associated with the nocturnal worsening of asthma. Journal of Allergy and Clinical Immunology 2003;112(3):513517.
- Arangino S, Cagnacci A, Angiolucci M, Vacca AMB, Longu G, Volpe A, Melis GB. Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men. American Journal of Cardiology 1999;83(9):1417-1419. PubMed Randomisierte Studie
1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).
When using this product avoid taking with alcohol or products that cause drowsiness (Herxheimer and Petrie 2002; Holliman and Chyka 1997).
Von Health Canada zitierte Quellen (1)
- Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database of Systematic Reviews Issue 2 2002. Art. No.: CD001520. DOI: 10.1002/14651858.CD001520. [Accessed 2023 August 22]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958662/pdf/CD001520.pdf DOI
1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).
When using this product avoid driving or using machinery for 5 hours (Avery et al. 1998; Suhner et al. 1998b).
Von Health Canada zitierte Quellen (2)
- Avery D, Lenz M, Landis C. Guidelines for prescribing melatonin. Annals of Medicine 1998;30(1):122-130. PubMed Übersichtsartikel
- Suhner A, Schlagenhauf P, Tschopp A, Hauri-Bionda R, Friedrich-Koch A, Steffen R. Impact of melatonin on driving performance. Journal of Travel Medicine 1998b;5(1):7-13. PubMed Randomisierte Studie
Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists for more than 4 weeks (chronic insomnia) (Buscemi et al. 2004; IOM 2004; Dipiro et al. 2002).
Von Health Canada zitierte Quellen (3)
- Buscemi N, Vandermeer B, Pandya R, Hooton N, Tjosvold L, Hartling L, Baker G, Vohra S, Klassen T. Melatonin for treatment of sleep disorders. Evidence Report/Technology Assessment No. 108. AHRQ Publication No. 05-E002-2. Rockville (MD): U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality. November, 2004.
- DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiological Approach. 5th edition. New York (NY): McGraw-Hill Co. Inc.; 2002.
- IOM 2004: Institute of Medicine Committee on the Framework for Evaluating the Safety of Dietary Supplements. Prototype monograph on melatonin. Dietary Supplement Ingredient Prototype Monographs, Developed as Examples for the Report Dietary Supplements: A Framework for Evaluating Safety. Institute of Medicine and the National Research Council of the National Academies, Washington (DC): National Academies Press 2004: D1-D71.
Gegenanzeigen
Do not use if you are pregnant or breastfeeding (IOM 2004).
Von Health Canada zitierte Quellen (1)
- IOM 2004: Institute of Medicine Committee on the Framework for Evaluating the Safety of Dietary Supplements. Prototype monograph on melatonin. Dietary Supplement Ingredient Prototype Monographs, Developed as Examples for the Report Dietary Supplements: A Framework for Evaluating Safety. Institute of Medicine and the National Research Council of the National Academies, Washington (DC): National Academies Press 2004: D1-D71.
Bekannte Nebenwirkungen
Stop use if allergy occurs or if you experience headache, confusion, or nausea (Herxheimer and Petrie 2002).
Von Health Canada zitierte Quellen (1)
- Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database of Systematic Reviews Issue 2 2002. Art. No.: CD001520. DOI: 10.1002/14651858.CD001520. [Accessed 2023 August 22]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958662/pdf/CD001520.pdf DOI
Sie betreffen die Zutat, nicht dieses Produkt oder seine Dosis. Sie ersetzen keinen ärztlichen Rat.
Andere Meldungen mit demselben Namen
Dieser Name wird von mehr als 10 Meldungen verschiedener Unternehmen verwendet und bezeichnet kein bestimmtes Produkt. Alle Meldungen mit diesem Namen ansehen.
Marke : Biophénix
Ist eine Angabe zu diesem Produkt falsch oder veraltet, ob Sie Leser oder Marke sind? Schreiben Sie an contact@compoatlas.com: Jede Korrektur wird im Korrekturprotokoll veröffentlicht.